Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. (NYSE: RMD) drives innovation in digital health and respiratory care through cloud-connected medical devices and remote patient management platforms. This news hub provides investors and healthcare professionals with timely updates on the company's market activities and clinical advancements.
Access curated press releases, earnings reports, and regulatory filings alongside analysis of product launches and partnership announcements. Our repository tracks developments across ResMed's core focus areas: sleep apnea solutions, COPD management technologies, and out-of-hospital care software platforms.
Stay informed about FDA clearances, clinical trial results, and global market expansions through verified sources. The page serves as a comprehensive resource for monitoring ResMed's progress in merging medical device engineering with data-driven healthcare solutions.
Bookmark this page for streamlined access to strategic updates impacting respiratory care innovation and digital health investment opportunities. Check regularly for new developments in ResMed's mission to transform chronic disease management worldwide.
ResMed presented 13 new clinical studies at SLEEP 2024, highlighting the effectiveness of PAP therapy for Obstructive Sleep Apnea (OSA) and comorbid insomnia (COMISA). Key findings include a 31% reduction in hospitalizations and a 23% decrease in ER visits among COMISA patients adhering to PAP therapy. The research also revealed a 17% prevalence of insomnia in adults across North America, Latin America, and the Caribbean, and higher rates of depression in women with OSA. The studies underscore the importance of sleep health and PAP therapy in improving patient outcomes.
New research supported by ResMed, presented at the American Thoracic Society (ATS) 2024 International Conference, highlights the effectiveness of Positive Airway Pressure (PAP) therapy in reducing risks of death and hospitalization in patients with obstructive sleep apnea (OSA). Notable findings include a 37% reduction in mortality for PAP-treated OSA patients and a projection that OSA prevalence in the U.S. will rise by 26.7% among adults aged 30-70 by 2050. Additional studies reveal that adherence to GLP-1 medications correlates with higher PAP therapy usage, and adaptive servo-ventilation (ASV) therapy improves quality of life for patients with treatment-emergent central sleep apnea (TE-CSA) and opioid-induced central sleep apnea. The research underscores the critical role of PAP therapy in managing sleep disorders and improving cardiovascular health outcomes.
ResMed will present 26 abstracts at the American Thoracic Society (ATS) 2024 conference in San Diego, highlighting the increasing prevalence of obstructive sleep apnea (OSA) and the critical role of Positive Airway Pressure (PAP) therapy. Key sessions include studies on the impact of PAP therapy on hospitalization, mortality in OSA patients, and the prevalence of OSA into 2050. The event will showcase digital innovations and patient-centric approaches in respiratory care, featuring the latest ResMed products like the AirCurve 11 Bilevel Devices and the AirFit F40 CPAP mask.
ResMed (RMD) announced its participation in the RBCCM Global Healthcare Conference with key company executives discussing key topics. The event will be held on May 14, 2024, at InterContinental New York Barclay. More details and webcast access are available on ResMed's investor relations website.
FAQ
What is the current stock price of Resmed (RMD)?
What is the market cap of Resmed (RMD)?
